Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on IN8bio. The associated price target was lowered to $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy’s rating is based on the anticipation of promising developments in IN8bio’s pipeline, particularly the upcoming preclinical data for INB-619 targeting cancer and autoimmune diseases expected in the fourth quarter of 2025. The company’s strategic updates on the enrollment and clinical progress of its Phase 1 and 2 trials for INB-100, INB-200, and INB-400 further support the positive outlook.
Additionally, the recent reverse stock split and subsequent adjustments in the valuation model have led to a price target of $3, reflecting a calculated approach to the company’s financial projections. The current cash position, projected to sustain operations into mid-2026, and the valuation based on discounted cash flow and other metrics, suggest a favorable risk-reward scenario. These factors collectively underpin the Buy rating, indicating confidence in IN8bio’s potential to achieve significant milestones in the coming years.
According to TipRanks, Roy is an analyst with an average return of -23.6% and a 19.52% success rate. Roy covers the Healthcare sector, focusing on stocks such as Enliven Therapeutics, Nuvation Bio, and Prime Medicine, Inc..